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DEPLETION OF L2PB1 CELLS INCREASES ABDOMINAL INFLAMMATION, 
BLOOD LIPIDS, AND GLUCOSE INTOLERANCE IN DIO MICE 
JORDAN ALISON NEWMARK 
 
ABSTRACT 
L2pB1 cells are a subset of B-1 B lymphocytes expressing programmed death 
ligand 2 (PD-L2) on their surface. They constitute 30-50% of B lymphocytes in the 
mouse peritoneal cavity and contribute to the production of natural IgM antibody. 
Previous studies have indicated a protective role of B-1 B cells in attenuating 
atherosclerosis and insulin resistance. We report that L2pB1 cells possess a unique IgM 
antibody specificity for phosphorylcholine (PC) and phosphatidylcholine (PtC) IgM 
enabling them to perform PC- and PtC-specific phagocytosis of PtC-nanoparticles. Here 
we demonstrate that induced depletion of L2pB1 in a transgenic mouse model with 
L2pB1-specific diphtheria toxin receptor (DTR) expression increases abdominal 
inflammation in the peritoneal cavity as well as the visceral adipose tissue in diet-induced 
obese (DIO) mice. L2pB1-depleted DIO mice also display increased triglycerides and 
blood glucose levels per gram of body weight relative to PBS-injected control DIO mice. 
Our results suggest that L2pB1 cells may play a role in anti-inflammatory regulation in 
DIO. Further investigation is required to discover how L2pB1 cells protect from obesity-
induced inflammation and whether L2pB1 cells can provide cellular therapy to control 
chronic inflammation in obese patients. 
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INTRODUCTION 
 Obesity is an epidemic that is increasingly becoming recognized as an 
inflammatory disease. It presents with a wide range of clinical manifestations and co-
morbidities, including but not exclusive to: diabetes mellitus type 2, hypertension, 
hypercholesterolemia, atherosclerosis, stroke, obstructive sleep apnea, chronic renal 
disease, non-alcoholic fatty liver disease, multiple types of cancers, and immune 
dysfunction from secretion of adipokines (Redinger, 2007). High fat diet (HFD) not only 
up-regulates B2 lymphocytes and adipokines shown to promote widespread inflammation 
and atherosclerotic lesions, but also induces depletion and dysregulation of B-1 B 
lymphocytes important in maintaining tissue homeostasis (Kaminski & Randall, 2010) 
(Vo et al., 2014). Evidence indicates that B-1 B lymphocytes are important in 
maintaining tissue homeostasis, but the extent of their protective effects is unknown and 
may be altered by HFD (Vo et al., 2014). This study seeks to determine the homeostatic 
functions of a particular subset of B-1 B cells by comparing the effects of HFD on 
glucose tolerance and abdominal inflammation in a transgenic mouse model with normal 
or targeted depletion of L2pB1 cells. 
Obesity and Adipose Tissue 
 With 68.5% of adults overweight or obese, obesity is one of the most prevalent 
health threats afflicting the United States, attributing for 18% of mortalities for adults 
ages 40 to 85 (Ogden, Carroll, Kit, & Flegal, 2014) (Grant & Dixit, 2015). Oversupply of 
fatty acids and glucose leads to inflammation and skews the immune system from anti-
inflammatory to pro-inflammatory subtypes (Redinger, 2007). 
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Excessive intake of free fatty acids (FFA) leads to storage in the form of 
triglyceride within adipocytes to protect against fatty acid toxicity in the blood leading to 
oxidative stress (Redinger, 2007). However, continuous lipolysis eventually results in the 
release of FFA, inducing lipotoxicity and inhibiting lipogenesis, leading to inadequate 
clearance of triglycerides from the serum (Redinger, 2007). This then results in insulin 
receptor dysfunction and subsequent insulin resistance (Redinger, 2007). Compounded 
with increased glucose intake, the resultant hyperglycemia increases inflammation, 
causes switching of anti-inflammatory M2 macrophages to pro-inflammatory M1 
macrophages, and decreases regulatory T cells in adipose tissue (Grant & Dixit, 2015). 
Levels of pro-inflammatory cytokines IL-6 and TNF-α are increased in overweight and 
obese individuals, while levels of anti-inflammatory adipokine adiponectin are decreased 
(Soodini & Hamdy, 2006).  
The actual structure of adipose tissue changes in obesity as well. Histological 
analysis reveals the presence of “crown-like structures” consisting of lymphocytes 
surrounding dead adipocytes (Grant & Dixit, 2015). Adipocyte death itself contributes to 
inflammation, as the exposed cytosolic constituents and lipid droplets releases danger-
associated molecular patterns (DAMPs) that activate pro-inflammatory macrophages 
(Grant & Dixit, 2015). The obesogenic state results in chronic inflammation of adipose 
tissue, alters the immune response, and thus may affect the obese individual’s 
immunological response to pathogens.  
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L2pB1 Cells 
B-lymphocytes are the cells of the adaptive immune system responsible for 
secreting antigen-specific antibodies. They are comprised mostly of follicular, marginal 
zone B2 cells (Abbas, 133). However, recent studies indicate that B-1 B cells may be 
derived from a totally different lineage during hematopoiesis (Ghosn et al., 2016). These 
B-1 B cells reside mostly in the peritoneum and mucosal tissues and are the major source 
of natural IgM and T-independent immune response to non-protein antigens with IgM 
antibodies (Abbas, 133).  
B1 B cells are the principle source of IL-10, an anti-inflammatory and regulatory 
interleukin that may promote autoimmunity (Baumgarth, 2011). B-1 B cells are 
subdivided into CD5-expressing B-1a cells that constitutively secrete over 80% of natural 
IgM antibody important for innate immunity, and B1b cells that do not express CD5 
(Zhong & Rothstein, 2011) (A B Kantor & Herzenberg, 1993) (Vas, Grönwall, & 
Silverman, 2013). B-1a cells are positively selected for self-reactivity involved in 
limiting the production of inflammatory cytokines (Baumgarth, 2011). Upon T-cell 
independent stimulation of their B-cell receptor (BCR), B-1a cells secrete IgM that binds 
to epitopes on apoptotic cells as well as encapsulated bacteria and stimulates adaptive 
IgG (Gray & Gray, 2015) (Baumgarth, 2011). After encountering apoptotic cells, B-1a 
cells secrete anti-inflammatory IL-10 that induces tolerance in autoreactive T-cells (Gray 
& Gray, 2015). 
A subset of B-1a cells constitutively expresses programmed death ligand-2 (PD-
L2) that is usually found on dendrites and macrophages in response to autoreactive T 
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cells. PD-L2 binds to programmed death-1 (PD-1) receptor that negatively regulates T-
cell activation and enables T-cell tolerance (Zhang et al., 2006). Zhang et al. (2006) 
demonstrate that PD-L2 knock out mice display heightened levels of T-cell activation and 
inflammatory cytokines IFN-γ and TNF-α produced by antigen-presenting cells both in 
vivo and in vitro.  
While the role of PD-L2 on these PD-L2 positive B-1a cells (L2pB1 cells) is not 
clearly defined, it is possible that the ligand may contribute towards these cells’ role in 
down-regulation of the immune response. L2pB1 cells produce anti-bacterial VH11/VH12 
immunoglobulins specific for phosphatidylcholine (PtC) and VH7-1 (VHS107) 
immunoglobulins specific for phosphorylcholine (PC), both major components of interior 
cell membranes (Zhong, Tumang, Gao, Bai, & Rothstein, 2007) (M. Yano & Pirofski, 
2011). Upon initiation of apoptosis, the conformation of the PC head group on PtC 
changes, marking it as a target for anti-PC or anti-PtC antibody recognition (Vas et al., 
2013). L2pB1 cells are particularly active in performing PC- and PtC-specific 
phagocytosis of senescent or apoptotic cells with compromised membranes, important for 
maintaining tissue homeostasis and reducing inflammatory cytokines released by 
apoptotic cells (Vo et al., 2014).  
Unique L2pB1 IgM Repertoire 
The IgM repertoire of L2pB1 cells is most distinctive for its production of anti-
PC- and anti-PtC-specific IgM antibodies. A study by Wilson et al. involving injection of 
a filiarial PC-containing glycoprotein demonstrates that the IL-10-releasing anti-PC IgM 
response is unique to B1 B cells and does not arise from other conventional B cells 
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(Wilson, Katz, Goodridge, M. Harnett, & Harnett, 2003). Unlike most antibodies, the 
majority of IgM antibodies produced by B1 cells arise from the germ line rather than 
somatic hypermutation (Masahide Yano & Pirofski, 2011). Only a select few 
combinations of heavy and light chain genes in the variable region and the CDR3 region 
are specific for PC or PtC. PC-reactive monoclonal antibodies (mAbs) are constituted of 
the murine gene family s107 for the variable heavy chain (VH) and three murine variable 
light chain (VL) gene families: VK4, VK7, and VK8 (Masahide Yano & Pirofski, 2011). The 
heavy and light chains of PtC-reactive mAbs are usually encoded by VH11-VK9 or VH12-
VK4/5 (Seidl et al., 1997). The anti-PtC heavy and light IgM chains display non-random 
identical rearrangements likely attributable to double homology at the coding joints, 
resulting in a limited repertoire of PtC-reactive MAbs (Seidl et al., 1997).  
This limited repertoire, however, enables L2pB1 cells to exhibit specificity for 
apoptotic cells and be particularly useful in decreasing cardiovascular episodes and 
necrotic cores of atherosclerotic lesions (Kyaw et al., 2011). 
B1 Cells and Obesity 
 In HFD-fed mice, B1 B cell frequency is decreased in the peritoneal cavity and 
visceral adipose tissue, whereas pro-inflammatory B2 cell frequency is increased (Shen et 
al., 2015). Additionally, the normally protective role of B1 B cells can become altered in 
obesity, contributing to immune dysfunction. With HFD, L2pB1 cells display non-
discriminatory phagocytosis rather than PtC-specific phagocytosis (Vo et al., 2014). 
While this “B1-to-macrophage-like transition” may hasten the clearance of lipids and 
other cellular excretions released during obesity-induced inflammation of adipose tissue, 
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it comes at the expense of tissue homeostasis provided by PtC-specific phagocytosis (Vo 
et al., 2014). This transformation may explain the mechanism by which peritoneal B1 B 
cell count decreases with HFD (Hall et al., 2012).  
Obesity-induced B1 cell depletion also results in diminution of anti-inflammatory 
IL-10 production, since B-1a cells are the major source of this interleukin. Shen et al. 
(2015) reported that transfer of B-1a cells to B-1a-deficient mice improves insulin 
resistance and glucose intolerance induced by HFD through secretion of IL-10 and IgM. 
While supplementation with B2 cells tends to worsen the metabolic dysfunction, up-
regulation of B1 cells may reduce inflammation, susceptibility to infection, and insulin 
resistance associated with obesity (Shen et al., 2015).  
B-1a cells have other anti-pathogenic implications as well. Hosseini et al. (2015) 
demonstrated that phosphatidylserine stimulation of peritoneal B-1a cells helped alleviate 
atherosclerotic lesions through secretion of polyreactive IgM antibodies that promote 
clearance of apoptotic cells and target T-cells and oxidized low-density lipoproteins to 
attenuate inflammation (Hosseini et al., 2015). More specifically, high levels of anti-PC 
IgM in patients with systemic lupus erythrematosus was correlated with reduced history 
of atherosclerotic cardiovascular disease (Grönwall et al., 2012). Anti-PC IgM antibodies 
produced primarily by L2pB1 cells appear to be particularly protective for cardiovascular 
diseases compared to polyreactive IgM (Grönwall et al., 2012).  
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SPECIFIC AIMS AND OBJECTIVES 
 While obesity has been shown to deplete B-1 B cells and diminish their function, 
the extent of the effects B-1 cells have on obesity is uncertain. To determine the 
mechanism by which L2pB1 cells perform their protective roles in obesity, a transgenic 
murine model has been constructed to induce selective depletion of PD-L2+ B1 cells. In 
control and L2pB1 cell-depleted mice with diet-induced obesity (DIO), we will determine 
the extent to which L2pB1 cells: 
• Influence tissue homeostasis by measuring the relative levels of 
granulocytes in L2pB1-depleted versus control mice. 
• Affect weight gain by comparing absolute and rate of weight gain in 
L2pB1-deficient versus control mice. 
• Alter obesity-induced glucose intolerance and insulin resistance by 
comparing fasting blood glucose and serum insulin levels of L2pB1-
depleted and control mice. 
• Alter serum total cholesterol and triglyceride levels in L2pB1 cell-
depleted versus control mice.  
We hypothesize that L2pB1-depleted mice will exhibit significantly higher levels 
of inflammation, greater weight gain, and higher fasting blood glucose than control mice. 
We hope to qualify and quantify the protective mechanisms of B-1 cells in obesity and 
suggest a mechanism by which B-1 cells may be utilized therapeutically to ameliorate 
obesity-induced immune dysfunction. 
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METHODS 
Mice 
C57BL/6J were purchased from The Jackson Laboratory and bred to express the 
CD19 Cre-PDL2-ZsGreen-TdTomato-DTR (CD19 Cre-PZTD) genotype developed in 
our animal model. All mice used were age-matched males. The mice were housed in a 
pathogen-free, temperature-controlled environment on a 12-hour light/dark cycle and 
placed into separate cages to prevent food competition. The Boston University 
Institutional Animal Care and Use Committee approved all protocols. 
Animal Model 
In order to selectively deplete L2pB1 cells, Dr. Zhong’s laboratory has developed 
a murine model that expresses diphtheria toxin receptor (DTR) solely on PD-L2 positive 
B cells. Demircik et al. (Demircik, Buch, & Waisman, 2013) found that crossing induced 
DTR (iDTR) mice containing the gene for diphtheria toxin receptor to mice expressing 
Cre on their B cells (CD19-Cre) generated mice that expressed DTR on their B cells. 
Thus those B cells were susceptible to destruction by diphtheria toxin (DT). Therefore, 
upon injection with diphtheria toxin (DT), only L2pB1 cells will be depleted. 
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Fig 1. Transgenic mouse model. A ZsGreen cDNA copy of green fluorescent protein (GFP) 
gene was inserted downstream of the PD-L2 gene and floxed for Cre DNA recombinase-induced 
depletion. A TdTomato gene was also inserted downstream of PD-L2-ZsGreen gene separated by 
a stop codon. This allowed expression of ZsGreen gene in all PD-L2 expressing cells. When 
crossed to CD-19 Cre knock-in mice, all CD-19 expressing B cells will have ZsGreen depleted 
and express only TdTomato. As a result, all L2pB1 cells will fluoresce red while all other PD-L2 
expressing cells will fluoresce green. Figure taken from (Lee, Mao, Vo, Gao, & Zhong, 2015).   
 
L2pB1 Cell Depletion 
At 6 weeks of age, mice were given an intra-peritoneal (IP) injection of either 1X 
phosphate-buffered saline (PBS) (Invitrogen) for control mice or 25 ng/g body weight DT 
(Sigma-Aldrich, St. Louis) for DT mice over 4 consecutive days. In accordance to the DT 
injection protocol outlined in Demircik et al. (2013), DT was diluted in 1X PBS without 
calcium or magnesium to 2µg DT/mL. The appropriate volume of DT solution was 
calculated based on the weights of the mice before the DT was loaded into syringes and 
injected IP at 25ng/g body weight. Booster injections of DT or PBS were administered 3, 
6, and 9 weeks after the last day of the 4-day round of initial injections. Appropriate 
personal protective equipment and proper precautions were taken to minimize risk of 
exposure to the toxin. 
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High Fat Diet Schedule 
 
Fig 2. 45% High Fat Diet Schedule. CD19-Cre-PZTD DIO mice were injected with PBS or DT 
at 6-7 weeks of age with 4 consecutive injections followed by booster injections at 3, 6, and 9 
weeks. Mice were fed with 45 kcal% HFD for 12 weeks starting on the fourth day of initial 
injections. Mice were weighed on the first day of initial injections and every week on HFD. 
Blood was taken on the first day of initial injections and at weeks 3, 6, and 9. Mice were 
sacrificed on week 12 and blood and tissues obtained for analysis. 
 
On the last day of DT or PBS injections, the mice began a 12-week regimen of 
45% HFD (45 kcal% fat, Research Diets, Inc.). Body weights were collected weekly, and 
blood samples were obtained from the tail before the 4-day injection period, and also at 
weeks 3 and 9 on HFD. To collect the blood, mice were briefly dosed with isoflurane 
(Henry Schein, OH) before severing the very tip of the tail, from which ~50µL total of 
blood droplets were collected. Blood samples were stored at room temperature for 45 
minutes and then spun down twice at 8,500 RPM for 10 minutes to isolate the serum. 
Serum samples were stored at -20°C. 
Glucose Tolerance Test 
Glucose tolerance tests (GTT) were performed at weeks 6.5 and 11.5 on HFD. 
Mice were weighed and deprived of food and water for 6 hours prior to the GTT. D-(+)-
glucose (Sigma) was dissolved in PBS to a concentration of 250mg/mL. Mice were dosed 
briefly with isoflurane before cutting the tip of the tail to obtain baseline blood levels 
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immediately prior to IP injection of the glucose solution at 1g/kg body weight. Blood 
glucose levels were measured with a Contour glucometer and glucose strips every 15 
minutes after injection for 90 minutes. The tip of the tail was wiped clean before and after 
blood collection. 
Tissue Collection and Processing 
Mice were sacrificed after 12 weeks on 45% HFD. Serum was collected for lipid 
analysis via cardiac puncture. PCW, spleen, thymus, omentum, and perigonadal fat were 
collected for FACS (fluorescence-activated cell sorting) staining. Inguinal lymph nodes, 
kidney, liver, pancreas, and heart were placed in formalin overnight, then transferred to 
70% ethanol before being processed and embedded in paraffin for future 
immunohistochemistry (IHC) analysis with hematoxylin and eosin.  
Peritoneal cells were obtained via peritoneal cell washout with Hank’s Balanced 
Salt Solution (HBSS) (Gibco, MA) supplemented with 2% Fetal Bovine Serum (FBS) 
(Aleken Biologicals, TX). 10mL of HBSS + 2% FBS was injected into the peritoneal 
cavity and the mouse was shaken to release cells into the fluid. The PCW was then 
extracted with a 23G needle attached to a syringe. PCW cells were centrifuged for 6 
minutes at 1200 RPM and resuspended in FACS buffer (1X PBS with 2%FBS) for FACS 
staining. 
 Cells were extracted from the spleen and thymus by gently grinding the tissues 
between two microscope slides. The cells were washed and suspended in R10 media 
(RPMI supplemented with 2% FBS, 2% HEPES, 1 unit/mL penicillin/streptomycin, and 
1 unit/mL L-glutamine). Spleen cells were centrifuged for 6 minutes at 1200 RPM and 
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resuspended in 1mL erythrocyte lysis buffer (Qiagen, Germany) for 5 minutes at room 
temperature to lyse any red blood cells in the sample. After quenching the lysis buffer 
with 9mL cold R10, the cells were spun, resuspended in 3mL R10, and counted using a 
hemocytometer. Cells were resuspended in 2 million cells/25µL FACS buffer for FACS 
staining. Thymus cells were processed identically to spleen cells if the thymus was 
bloody when collected; if not, the erythrocyte lysis step was skipped.  
Perigonadal adipose tissue was weighed and one section set aside for IHC while 
the remainder was placed in HBSS with 2% FBS for fat digestion. Adipose tissue and 
omentum were cut into <1mm2 pieces and washed with HBSS. Type IV collagenase 
(Worthington Biochemical) was added in an equal ratio to HBSS, then incubated in a 
shaker at 37°C for 45 minutes. The samples were centrifuged for 6 minutes at 1200 RPM, 
and the floating fat and supernatant was removed. The cell pellet was resuspended in 
HBSS, passed through a 70µm cell strainer to remove adipocytes, then spun again and 
resuspended in FACS buffer for FACS staining. 
Flow Cytometry 
Cells obtained from the peritoneal cavity, thymus, spleen, omentum, and 
perigonadal adipose tissue were suspended in FACS buffer and placed in a round bottom 
96-well plate for staining. 25µL of CD16/32 Fc blocker (BioLegend, CA) was added and 
the cells were incubated on ice for 15 minutes.  
Cells were stained for 45 minutes with the following mix of dyes and primary 
antibodies: Ghost Dye Violet 510 (Tonbo Biosciences, CA) as a live/dead cell marker; 
B220 PerCP Cy5.5 (eBioscience, CA), CD19 BUV935 (BD Biosciences, CA), and 
 13 
CD11b APC e780 (eBioscience, CA) as B cell markers; CD5 PE Cy7 (eBioscience, CA) 
as a CD5 expression marker for B-1a B cells; IgM APC (eBioscience, CA) as a marker 
for cells expressing IgM; and PD-L2 BV421 (BD Biosciences, CA) as a PD-L2 
expression marker. Autofluoresence from ZsGreen and TdTomato were also detected, but 
no antibody was used.  
Single-stained controls were prepared using OneComp eBeads (Affymetrix, CA). 
Compensation beads were vortexed and one drop was added to the plate for each control. 
CD11b APC e780, B220 PerCP Cy5.5, CD19 BUV395, or IgM APC antibody was added 
each in a 1:100 dilution to one drop of compensation beads, while PD-L2 BV421 was 
added in a 1:500 dilution and CD5 PE Cy7 in a 1:2500 dilution. Ghost Dye Violet 510 
was added in a 1:250 dilution to spleen cells as a live/dead control. Unstained PCW cells 
in FACS buffer with 1% formalin served as a negative control. Controls were incubated 
for 30 minutes on ice.  
The plate containing cells, single-stained controls, and negative controls was 
centrifuged for 6 minutes at 1200 RPM. The supernatant was removed and both cells and 
beads were washed twice with 150µL FACS buffer, centrifuging between washes. The 
samples were suspended in 300µL FACS buffer with 1% formalin and fixed overnight, 
covered, at 4°C until FACS was performed. FACS samples were collected on BD LSRII 
and then analyzed using FlowJo Software (TreeStar, OR).  
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Cholesterol and Triglyceride Metabolite Analysis 
80µL of serum gathered from each mouse at the 12-week end point was inserted 
into a cuvette with cholesterol and triglyceride slides (IDEXX Laboratories Inc., ME) and 
run through an IDEXX Chemistry Analyzer to determine total cholesterol and 
triglyceride levels in each mouse after 12 weeks on 45% HFD. The machine-generated 
serum concentrations were then analyzed in Microsoft Excel.  
Statistical Analysis 
Student’s 2-tailed unpaired t-test generated in Microsoft Excel was utilized to 
calculate statistical significance for differences in percent body weight gain, blood 
glucose levels, serum cholesterol and triglyceride levels, and percent L2pB1 cells and 
granulocytes for control and L2pB1-depleted mice. For all tests, p < 0.05 was considered 
to be statistically significant.  
 Some mice deviated outside the normal range for certain aspects, such as percent 
body weight gain, blood glucose levels, and serum lipid levels. Upper and lower outliers 
were calculated using a formula based on 1.5 times the inter-quartile range (IQR). Mice 
that were repeatedly calculated to be outliers were removed from the calculations to 
avoid skewing the data.  
 IQR: Quartile 3 – Quartile 1 
Low outlier: Quartile 1 – (1.5 x IQR) 
 High outlier: Quartile 3 + (1.5 x IQR) 
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 For FACS data analysis and granulocyte percentages, only mice with the same 
FACS staining and cytometer settings were used. None of these mice were considered 
outliers and thus were also part of the larger group data for percent body weight gain, 
lipidomics, and glucose tolerance calculations.  
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RESULTS  
FACS Analysis  
 In order to compare differences in body weight gain, glucose tolerance, lipid 
levels, and inflammatory markers, flow cytometry was first used to confirm L2pB1-
depletion of DT-injected relative to control mice.  
A 9-color FACS panel was used to identify L2pB1 cells in the PCW, perigonadal 
adipose tissue, omentum, spleen, and thymus of PBS- and DT-injected mice. L2pB1 cells 
are found primarily in the peritoneal cavity, so data analysis for confirmation of L2pB1 
cell depletion in DT-injected mice compared to controls focused on PCW.  
CD5+, B220+ B-1a cells were selected from the live single lymphocytes. B-1a 
cells were then gated on IgM and PD-L2 to obtain the percentage of double-positive 
L2pB1 cells (see Fig 3). PBS-injected mice were seen to have an average 23.52% of 
L2pB1 cells, while DT-injected mice had an average 6.43% L2pB1 cells, equating to 
72.66% L2pB1-depletion.  
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Fig 3. PCW FACS gating strategy. CD19-Cre-PZTD DIO mice were injected with PBS or DT 
at 6-7 weeks of age with 4 consecutive injections followed by booster injections at 3, 6, and 9 
weeks. Mice were fed with 45 kcal% HFD for 12 weeks. Cells were stained for FACS analysis. 
A) Lymphocytes were first gated out of all PCW cells based on size and granularity. B) Single 
cells were then gated by granularity (SSC) (B) and size (FSC) (C). D) Live cells that stain 
negative for the live/dead Ghost Dye 510 were gated from single lymphocytes. E) CD5+, B220+ 
B-1a cells were selected from the live single lymphocytes. F) The percentage of IgM+, PD-L2+ 
B-1a lymphocytes was obtained from the double-positive gate (bottom right).  
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Fig 4a. FACS analysis of peritoneal L2pB1 cells in PBS- and DT-injected CD19-Cre-PZTD 
DIO mice. CD19-Cre-PZTD DIO mice were injected with PBS or DT at 6-7 weeks of age with 4 
consecutive injections followed by booster injections at 3, 6, and 9 weeks. Mice were fed with 45 
kcal% HFD for 12 weeks. Cells were stained for FACS analysis. Depicted is a representative 
FACS image of L2pB1 cells from PCW of PBS-injected (Control) and DT-injected (Depleted) 
mice, respectively. The percentage of IgM-positive PD-L2-expressing L2pB1 cells out of all 
CD5+, B220+ B-1a lymphocytes is noted in the top right quadrant. The red arrow points to the 
L2pB1 cell population, which is mostly missing in the DT-injected mouse.  
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Fig 4b. Comparison of the percentage of L2pB1 cells in total peritoneal B-1a lymphocytes in 
PCW of PBS- and DT-injected CD19-Cre-PZTD DIO mice. CD19-Cre-PZTD DIO mice were 
placed on the previously mentioned injection and 12-week HFD schedule (see Fig 4a). Peritoneal 
washout was obtained at week 12. Cells were stained for FACS analysis. The average percentage 
of L2pB1 cells in PCW is 23.52% for control (PBS) mice (n = 6) and 6.43% for L2pB1-depleted 
(DT) mice (n = 10) **(p < 0.01). The average depletion is 72.66%. 
 
While analyzing FACS samples for L2pB1 cell depletion, it was noted that the 
PCW and perigonadal adipose tissue of DT-injected mice displayed far greater 
percentages of highly granular cells than PBS-injected mice. This population of cells with 
high levels of side scatter was determined to negative for B cell marker CD19, indicating 
the presence of granulocytes such as neutrophils, eosinophils, and basophils (data not 
shown).  
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      PCW 
 
 
        Perigonadal Adipose Tissue 
 
Fig 5a. FACS analysis: PCW and perigonadal fat granulocyte percentages in PBS- and DT-
injected CD19-Cre-PZTD DIO mice. CD19-Cre-PZTD DIO mice were injected with PBS or 
DT at 6-7 weeks of age with 4 consecutive injections followed by booster injections at 3, 6, and 9 
weeks. Mice were fed with 45 kcal% HFD for 12 weeks. Single cell suspension was isolated from 
PCW and perigonadal adipose tissue. Depicted is a representative FACS image showing the 
granulocytes gate (green arrow) from PCW (top) and perigonadal adipose tissue (bottom) of 
control and L2pB1-depleted mice. Granulocyte percentage is noted at the top left corner above 
the encircled population. 
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Fig 5b. Granulocyte percentage in PCW of PBS- and DT-injected CD19-Cre-PZTD DIO 
mice. CD19-Cre-PZTD DIO mice were placed on the previously mentioned injection and 12-
week HFD schedule (see Fig 5a). Granulocyte percentage in PCW of each control (PBS) mouse 
(n = 6) is denoted by a blue diamond, while each red diamond denotes the granulocyte percentage 
in PCW of an L2pB1-depleted mouse (n = 10). The green bar indicates control mice average 
granulocyte percentage; the orange bar marks L2pB1-depleted mice average granulocyte 
percentage *(p < 0.05).  
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Fig 5c. Granulocyte percentage in perigonadal adipose tissue of PBS- and DT-injected 
CD19-Cre-PZTD DIO mice. CD19-Cre-PZTD DIO mice were placed on the previously 
mentioned injection and 12-week HFD schedule (see Fig 5a). Granulocyte percentage in 
perigonadal adipose tissue of each control mouse (n = 6) is denoted by a blue diamond, while 
each red diamond denotes the granulocyte percentage in fat of a L2pB1-depleted mouse (n = 10). 
The green bar indicates control mice average adipose granulocyte percentage; the orange square 
marks depleted mice average adipose granulocyte percentage **(p < 0.01).  
 
 DT-injected mice had a broader distribution of percentages, contributing to a 
greater standard error, than PBS-injected mice. This is largely attributable to the fact that 
data from two batches of DT-injected mice was used, while data from only one batch of 
PBS-injected mice was used. Despite the large error, DT-injected mice were determined 
to have a significantly greater percentage of granulocytes in both PCW (p < 0.05) and 
perigonadal fat (p < 0.01). Due to variations in FACS staining and voltages between 
batches of mice from which tissues were collected, data from some mice was discarded. 
Only data of mice of comparable staining and cytometer settings was used for FACS 
analyses. These mice were included in the larger group of mice analyzed for body weight, 
glucose tolerance, and serum lipid levels.  
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Body Weight 
 Mice body weights were recorded weekly over the course of the 12-week 45% 
HFD period. Although all mice were started on the HFD schedule between 6-7 weeks of 
age, initial body weights varied considerably. Therefore percent weight gain from the 
initial body weight was measured as opposed to the raw body weights.  
 Surprisingly, control PBS-injected mice exhibited a significantly greater percent 
body weight gain than DT-injected mice for weeks 1-5 (p < 0.01), 6, 8, and 10 (p < 0.05).  
 
Fig 6. Average percent body weight gain for PBS- and DT-injected CD19-Cre-PZTD DIO 
mice. CD19-Cre-PZTD DIO mice were injected with PBS or DT at 6-7 weeks of age with 4 
consecutive injections followed by booster injections at 3, 6, and 9 weeks. Mice were fed with 45 
kcal% HFD for 12 weeks. Body weights were collected weekly and percent body weight gain on 
45% HFD determined based on initial pre-HFD body weights. PBS-injected mice (n = 8) 
exhibited a significantly greater percent body weight gain than DT-injected mice (n = 13) for 
weeks 1-6, 8, and 10 on 45 kcal% HFD *(p < 0.05), **(p < 0.01).  
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Lipid Metabolites 
 Serum samples collected at the 12-week end point were analyzed for cholesterol 
and triglyceride concentrations. No significant difference in cholesterol and triglyceride 
levels was seen between the control and L2pB1-depleted mice; however, normalizing for 
differences in body weights between treatment groups revealed a significantly higher 
triglyceride/body weight index in the L2pB1-depleted mice (p < 0.05). 
 
Fig 7. Serum cholesterol/body weight and triglyceride/body weight indexes in PBS- and DT-
injected CD19-Cre-PZTD DIO mice. CD19-Cre-PZTD DIO mice were injected with PBS (n = 
8) or DT (n = 13) at 6-7 weeks of age with 4 consecutive injections followed by booster 
injections at 3, 6, and 9 weeks. Mice were fed with 45 kcal% HFD for 12 weeks. Lipidomics were 
performed on the IDEXX Chemistry Analyzer to measure cholesterol and triglyceride levels and 
then normalized for body weight *(p < 0.05).  
 
Glucose Tolerance 
 Glucose tolerance tests were administered to mice after 6.5 and 11.5 weeks on 
45% HFD. Blood glucose levels were measured immediately before glucose injection and 
every 15 minutes after injection for 90 minutes. No significant difference in blood 
glucose levels was detected between control and L2pB1-depleted mice, likely attributable 
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to great variation in blood glucose levels between individual mice. However, normalizing 
for body weight due to higher body weight averages in the control group revealed a 
significantly higher blood glucose/body weight index for DT-injected mice compared to 
PBS-injected mice at 6.5 weeks on HFD. Due to a higher variation in blood glucose 
levels, no significant difference in blood glucose/body weight index was observed at the 
glucose tolerance test performed at 11.5 weeks on HFD.  
 
Fig 8. Blood glucose/body weight index of PBS- and DT-injected CD19-Cre-PZTD DIO 
mice at 6.5 weeks on 45% HFD. CD19-Cre-PZTD DIO mice were injected with PBS (n = 8) or 
DT (n = 13) at 6-7 weeks of age with 4 consecutive injections followed by booster injections at 3, 
6, and 9 weeks. Mice were fed with 45 kcal% HFD for 12 weeks. Glucose tolerance tests were 
performed at weeks 6.5 and 11.5 on 45% HFD. Blood glucose levels were obtained before 
glucose injection and for every 15 minutes post injection for 90 minutes, then normalized for 
body weight *(p < 0.05), **(p < 0.01).  
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DISCUSSION 
L2pB1 Cell Depletion 
Utilization of a CD19-Cre (+/-)-PD-L2-ZsG-TdT-DTR mouse model allowed for 
near-depletion of L2pB1 cells with 4 consecutive days of DT injection and booster 
injections every 3 weeks. The presence of some L2pB1 cells may be attributable to the 
inability of IP DT injection to deplete progenitor cells in the bone marrow that do not yet 
express surface markers; however, this method of regeneration is unlikely since B-1 cells 
undergo very little de novo development in the bone marrow (Baumgarth, 2011). It is 
more likely that L2pB1 cells display varying levels of DTR and thus some cells were able 
to escape depletion to replenish the population through a self-renewal process. Since the 
last DT booster injection was administered 3 weeks prior to the 12-week end point when 
PCW and other tissues were harvested and stained for FACS to determine L2pB1 
depletion, it is possible that there was partial repletion of L2pB1 cells in the interim that 
resulted in an average of 72.66% depletion (Figure 4b).    
Abdominal Inflammation 
 While ablation of the L2pB1 population was incomplete, its depletion was 
nonetheless sufficient to cause significant changes in the immunological state of the 
mice. The increased granulocyte percentages observed in the PCW and adipose tissue of 
DT-injected mice relative to PBS-injected mice demonstrates the significance of L2pB1 
cells in controlling inflammation (Figure 4). Although not statistically significant, 
increased granulocyte percentages were also observed in the omentum, thymus, and 
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spleen of DT-injected mice compared to PBS-injected mice (data not shown), indicating 
that the inflammation was systemic and not limited to the site of injection.  
 Since L2pB1 cells constitute a large portion of the B-1a population that in turn 
produces the majority of natural IgM autoantibody in the body, depletion of these cells 
likely resulted in a severe decrease of anti-PC and anti-PtC IgM that tags apoptotic cells 
for phagocytosis. It can thus be hypothesized that recruitment of granulocytes can be 
attributed to a buildup of apoptotic cells that are not being phagocytosed, as well as a 
deficit of anti-inflammatory IL-10 normally produced by L2pB1 cells.   
Body Weight Gain 
 While evidence of abdominal inflammation in the peritoneal cavity and visceral 
adipose tissue is significant, the physiological manifestations of this inflammation remain 
obscure.  
We had reasoned that increased inflammation and reduction of apoptotic cell 
clearance associated with a decrease in natural IgM would compromise the body’s ability 
to compensate for increased FFA intake on HFD, resulting in greater rate of weight gain 
for L2pB1-depleted mice. Instead, the control mice exhibited a significantly greater 
percentage of body weight gain throughout the 12-week HFD period. This may be 
attributable to greater adipocyte death in L2pB1-depleted mice. 
In DIO mice, adipocyte death increases progressively with time on HFD, inducing 
total-body insulin resistance, macrophage expression of pro-inflammatory adipokines, 
and down-regulation of anti-inflammatory adiponectin (Strissel et al., 2007). Since 
adipocyte death increases with increasing levels of inflammatory cytokines, it is possible 
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that excessive inflammation such as that seen in PCW and perigonadal adipose tissue 
may induce adipocyte death. Increased death of adipocytes may in turn lower rate of 
body weight gain. Other physiological responses to this increased inflammation and 
possible adipocyte death may have been present, such as diarrhea, but went unnoticed 
since they were not looked for. 
However, previous experiments in which PBS- and DT-injected mice were placed 
on 60% HFD rather than 45% HFD exhibited slightly greater percent body weight gain in 
DT-injected mice over PBS-injected mice. Adipocyte death may still have been 
accelerated in L2pB1 depleted mice compared to controls; however, the extremely high 
percentage of fat in the diet may have overwhelmed the effects of adipocyte death. The 
increased recruitment of macrophages to clear dead adipocytes may instead have allowed 
more room for adipose tissue expansion (Strissel et al., 2007).   
Another batch of mice not included in this experiment were also placed on a 12-
week 45% HFD schedule, but were housed together rather than in individual cages; were 
weighed only pre-injection and at weeks 3, 6, 9, and 12; had blood taken only pre-
injection and during cardiac puncture at the 12-week end point; and had a GTT 
performed only at 11.5 weeks on HFD. In this group, DT-injected mice actually had a 
slightly higher percent body weight gain than PBS-injected mice, although it was not 
significant. This is more consistent with the results seen for previous experiments in 
which mice were fed a 60% HFD. Like the 60% HFD mice, these mice were housed 
together, rather than in the individual cages the 45% HFD mice were placed in for the 
purpose of preventing food competition. The same phenomenon was observed for mice in 
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the same experiment that were placed on an 18 kcal% fat control diet (CD) rather than on 
45 kcal% HFD. Mice in the DT-injected CD group were housed together, but mice in the 
PBS-injected CD group were housed individually to prevent fighting between non-sibling 
males. The DT-injected CD group gained significantly (p < 0.05) more percent body 
weight than the PBS-injected group after 3 weeks on CD, and slightly (but not 
significantly) more at 6 weeks on CD (data not shown). However, PBS-injected mice 
then gained slightly (but not significantly) more percent body weight than the DT-
injected mice at 9 and 12 weeks on CD. This is the opposite of the pattern observed with 
the 45% HFD mice that were housed together for the same experiment.  
It is possible, then, that there is an effect of behavior or social anxiety that causes 
the DT-injected mice to either eat less when housed individually, or the PBS-injected 
mice to eat more when housed individually. We are unsure as to why the trend varies for 
type of injection based on individual or grouped housing. Yamada et al. (2000) show 
opposite trends in weight gain for isolated versus group-housed mice of different 
genotypes: wild type compared to mice deficient in bombesin receptor subtype-3 (BRS-
3). Their results suggest that BRS-3 expression in the central nervous system (CNS) may 
alter neural mechanisms for isolation behavior (Yamada, Ohki-Hamazaki, & Wada, 
2000). Although the mice used in our experiments are of the same mouse model and 
genotype, it is possible that L2pB1 depletion or DT injection itself may alter normal 
feeding behavior for isolated versus group-housed animals. Effects of DT injection on 
behavior warrant future study.    
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Lipid Metabolites and Glucose Intolerance 
 Since cholesterol, triglyceride, and blood glucose levels increase concordantly 
with increased body fat, these levels in fatter PBS-injected mice were not significantly 
different from those observed in the lighter DT-injected mice. Serum lipid and blood 
glucose levels were high for all mice, with a main effect of body weight rather than 
treatment condition. Once normalized for body weight, however, triglyceride/BW and 
blood glucose/BW indexes were revealed to be significantly higher for DT-injected mice. 
This indicates that despite reducing percent body weight gain, L2pB1-depletion 
exacerbates obesity-related pathologies such as hypertriglyceridemia and glucose 
intolerance.  
 Blood glucose levels and blood glucose/body weight index measurements were 
not significantly different between PBS- and DT-injected groups for the GTT performed 
after 11.5 weeks on HFD. The variation in blood glucose values rendered the error too 
large to accommodate a significant difference. This problem was perhaps due to the fact 
that the GTT was performed 2.5 weeks after the most recent injection, whereas the GTT 
at 6.5 weeks on HFD was performed only 0.5 weeks after the latest injection. In that 2.5-
week interim, it is possible that some L2pB1 cells regenerated and decreased the 
difference between treatment groups, enabling individual variation to become greater 
than between groups differences. 
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Future Studies 
 Additional analyses of serum and tissue are already being implemented to provide 
more concrete data on L2pB1-cell depletion and its effects in various tissues.  
The ELISA that was originally intended to be included in this study will be 
performed once more on the plates corresponding to those for which the protocol was 
written, enabling calculation of the anti-PC IgM concentrations in the serum samples. 
With this data, we will be able to ascertain whether anti-PC IgM concentration decreased 
in DT-injected mice compared to PBS-injected mice. Using serum samples from multiple 
time points on the 12-week HFD schedule (pre-injection, weeks 3, 9, and 12 on HFD) 
allows us to monitor the effects of DT-induced L2pB1 cell depletion on anti-PC IgM 
expression throughout the HFD schedule. 
 Discovery of increased granulocyte percentage in PCW and perigonadal adipose 
tissue of L2pB1-depleted mice encourages further identification of the extent of 
inflammation. Therefore, we intend to analyze inflammatory cytokines in serum samples 
to quantify the difference in these cytokine levels between mice treatment groups. 
 Although we have FACS data depicting inflammation in the peritoneal and 
adipose tissues, we are interested in studying visible changes in the perigonadal adipose 
tissue. We will perform histology analysis of the paraffin-embedded adipose tissue using 
hematoxylin and eosin immunohistochemistry staining. If there is indeed more 
inflammation in the L2pB1-depleted mice, we expect to observe more necrotic cells and 
crown-like structures of lymphocytes surrounding apoptotic adipocytes in the DT-
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injected mice. We are also interested in analyzing heart and liver tissues to look for signs 
of inflammation in DT-injected mice relative to PBS-injected mice. 
 As mentioned above, our FACS analysis revealed that DT-induced L2pB1 cell 
depletion was incomplete, likely due to self-renewal of some L2pB1 cells with slight 
variations in their DTR. Some repletion of L2pB1 cells is expected with a 3-week lapse 
between cell collection and DT injection; therefore we have decided to repeat the HFD 
schedule for only 10 weeks rather than 12, still with booster injections at 3, 6, and 9 
weeks. This will enable collection of tissues for FACS only 1 week after the last PBS or 
DT injection. In order to avoid frightening the mice during the GTT and causing 
unrelated blood sugar spikes, mice will be handled weekly to accustom them to being 
picked up and handled during the GTT. 
iRepertoire 
 In a previous experiment, PCW was collected from 3 control and 3 L2pB1-
depleted mice 2 weeks after they had been injected for 4 consecutive days with PBS or 
DT, respectively. The PCW was counted, centrifuged, and resuspended in RNAse 
inhibitor (Qiagen) before the samples were frozen and sent to iRepertoire (AL) for IgM 
sequencing. iRepertoire performed RNA extraction and sequenced the heavy and light 
IgM chains. All sequences were listed and quantified, and differences in sequence 
frequencies were compared between the PBS- and DT-injected mice.  
 iRepertoire frequencies were compared between control and L2pB1 depleted 
groups for the most common VH, VL, and VK sequences among anti-PC and anti-PtC 
antibodies. The data revealed significantly fewer anti-PC and anti-PtC frequencies 
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present in the DT-injected group compared to the PBS-injected group. This demonstrates 
the effects of L2pB1 cell depletion on the genetic level in terms of selectivity for IgM 
expression. 
 This data is in and of itself very exciting, but we are curious to determine the 
effects of both L2pB1-depletion and HFD on the IgM repertoire. We plan to institute a 
10-week experiment plan in which mice will receive initial injections of either PBS or 
DT for 4 consecutive days, followed by booster injections at weeks 3, 6, and 9. The mice 
will be placed into 4 categories: 
1) PBS-injection, 18 kcal% fat control diet (CD) 
2) DT-injection, 18 kcal% fat CD 
3) PBS-injection, 45 kcal% fat HFD 
4) DT-injection, 45 kcal% fat HFD 
Based on the results of the 2-week PBS- or DT- injection, we hypothesize that anti-PC 
and anti-PtC IgM sequence frequencies will be reduced in DT compared to control 
groups, and further reduced in HFD relative to CD groups given that HFD alone causes a 
decrease in L2pB1 cells (Shen et al., 2015).  
Conclusion 
 Through utilization of a CD19-Cre-PZTD DIO transgenic mouse model, we have 
verified L2pB1 cell depletion through 4 consecutive days of DT injection followed by 
booster injections every 3 weeks. Due to an unknown mechanism of self-renewal through 
variation on the DTR or lack of cell marker expression on progenitor cells in the bone 
marrow, some repletion of L2pB1 cells is witnessed after a 3-week lapse from the 
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previous injection. Despite this repletion, a significant increase of granulocyte percentage 
in the peritoneal cavity and perigonadal adipose tissue was still observed in L2pB1-
depleted mice compared to control mice. This suggests a potential anti-inflammatory 
regulation role of L2pB1 cells in controlling obesity-induced abdominal inflammation. 
Interestingly, DT-injected mice exhibit less body weight gain than PBS-injected 
control mice when placed in isolated housing, but this effect is reversed in group housing 
(based on data from previous experiments). This curious phenomenon has been witnessed 
in other studies such as Yamada et al., and indicates that L2pB1 cell depletion may 
influence factors of social interaction, isolation and feeding behavior, warranting future 
study. 
 Despite a smaller percentage body weight gain than control mice, L2pB1-depleted 
mice exhibit significantly higher serum triglyceride and blood glucose levels after 
normalization for body weight. Thus for mice of equal body weight, the L2pB1-depleted 
mice would have higher serum triglyceride and blood glucose levels than control mice. 
This suggests a significant role of L2pB1 cells in regulating obesity-induced increases in 
triglyceride levels and glucose intolerance.  
For future experiments, we will continue to monitor percent body weight gain, 
glucose tolerance, and serum lipid concentrations in PBS- or DT-injected mice on 10-
week 45% HFD placed in group housing rather than isolated housing. In order to avoid 
repletion of L2pB1 cells, a 10-week HFD schedule as opposed to a 12-week HFD 
schedule will be employed, resulting in only a 1-week lapse from last DT injection to 
tissue collection. 
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 L2pB1 cells appear to have a significant role in reducing obesity-induced 
abdominal inflammation, serum triglyceride levels, and glucose intolerance. Further 
studies are being pursued to determine the role of L2pB1 cells in regulating inflammatory 
cytokine levels in DIO mice. The physiological effects of this inflammation will be 
studied via histological analysis of visceral adipose tissue in L2pB1 depleted mice 
compared to control mice. Determination of the IgM repertoire of control versus L2pB1-
depleted mice on CD or HFD will reveal the extent of anti-PC and anti-PtC IgM 
production attributable to L2pB1 cells as well as cross interactions with obesity. The 
implications of the role of L2pB1 cells in regulating obesity-induced inflammation and 
the physiological effects on weight gain, serum lipids, and glucose intolerance is 
enormous. We are eager to embark on future investigations to determine the possibilities 
of utilizing L2pB1 cells as treatment for chronic abdominal inflammation in obese 
patients.  
 36 
REFERENCES 
Abbas, A. K. et al. (2014). Basic Immunology: Functions and Disorders of the Immune 
System. (4th ed., p. 133). Philadelphia, PA: Elsevier Saunders.  
A B Kantor, & Herzenberg,  and L. A. (1993). Origin of Murine B Cell Lineages. Annual 
Review of Immunology, 11(1), 501–538. 
http://doi.org/10.1146/annurev.iy.11.040193.002441 
Baumgarth, N. (2011). The double life of a B-1 cell: self-reactivity selects for protective 
effector functions. Nature Reviews Immunology, 11(1), 34–46. 
http://doi.org/10.1038/nri2901 
Demircik, F., Buch, T., & Waisman, A. (2013). Efficient B Cell Depletion via Diphtheria 
Toxin in CD19-Cre/iDTR Mice. PLoS ONE, 8(3), e60643. 
http://doi.org/10.1371/journal.pone.0060643 
Ghosn, E. E. B., Waters, J., Phillips, M., Yamamoto, R., Long, B. R., Yang, Y., … 
Herzenberg, L. A. (2016). Fetal Hematopoietic Stem Cell Transplantation Fails to 
Fully Regenerate the B-Lymphocyte Compartment. Stem Cell Reports, 6(1), 137–
149. http://doi.org/10.1016/j.stemcr.2015.11.011 
Grant, R. W., & Dixit, V. D. (2015). Adipose tissue as an immunological organ. Obesity, 
23(3), 512–518. http://doi.org/10.1002/oby.21003 
Gray, M., & Gray, D. (2015). Regulatory B cells mediate tolerance to apoptotic self in 
health: implications for disease. International Immunology, 27(10), 505–511. 
http://doi.org/10.1093/intimm/dxv045 
 37 
Grönwall, C., Akhter, E., Oh, C., Burlingame, R. W., Petri, M., & Silverman, G. J. 
(2012). IgM autoantibodies to distinct apoptosis-associated antigens correlate 
with protection from cardiovascular events and renal disease in patients with SLE. 
Clinical Immunology, 142(3), 390–398. http://doi.org/10.1016/j.clim.2012.01.002 
Hall, M., Zhu, A., Lovell, J., Aprahamian, T., Rifkin, I., & Zhong, X. (2012). Effects of 
high-fat diet on B1 B cells in obesity-associated inflammatory diseases. The 
Journal of Immunology, 188(Meeting Abstracts 1), 54.28. 
Hosseini, H., Li, Y., Kanellakis, P., Tay, C., Cao, A., Tipping, P., … Kyaw, T. (2015). 
Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis 
by expanding polyreactive IgM producing B1a lymphocytes. Cardiovascular 
Research, 106(3), 443–452. http://doi.org/10.1093/cvr/cvv037 
Kaminski, D. A., & Randall, T. D. (2010). Adaptive immunity and adipose tissue 
biology. Trends in Immunology, 31(10), 384–390. 
http://doi.org/10.1016/j.it.2010.08.001 
Kyaw, T., Tay, C., Krishnamurthi, S., Kanellakis, P., Agrotis, A., Tipping, P., … Toh, B.-
H. (2011). B1a B Lymphocytes Are Atheroprotective by Secreting Natural IgM 
That Increases IgM Deposits and Reduces Necrotic Cores in Atherosclerotic 
Lesions. Circulation Research, 109(8), 830–840. 
http://doi.org/10.1161/CIRCRESAHA.111.248542 
Lee, R. A., Mao, C., Vo, H., Gao, W., & Zhong, X. (2015). Fluorescence tagging and 
inducible depletion of PD-L2–expressing B-1 B cells in vivo. Annals of the New 
York Academy of Sciences, 1362(1), 77–85. http://doi.org/10.1111/nyas.12865 
 38 
Ogden, C. L., Carroll, M. D., Kit, B. K., & Flegal, K. M. (2014). Prevalence of 
Childhood and Adult Obesity in the United States, 2011-2012. JAMA, 311(8), 
806. http://doi.org/10.1001/jama.2014.732 
Redinger, R. N. (2007). The Pathophysiology of Obesity and Its Clinical Manifestations. 
Gastroenterology & Hepatology, 3(11), 856–863. 
Seidl, K. J., MacKENZIE, J. D., Wang, D., Kantor, A. B., Kabat, E. A., Herzenberg, L. 
A., & Herzenberg, L. A. (1997). Recurrent Identical Rearrangement and Repeated 
Expression of Identical Heavy and Light Chains in Single Anti-
phosphatidylcholine B Cells. Annals of the New York Academy of Sciences, 815(1 
B-Lymphocytes), 484–488. http://doi.org/10.1111/j.1749-6632.1997.tb52110.x 
Shen, L., Chng, M. H. Y., Alonso, M. N., Yuan, R., Winer, D. A., & Engleman, E. G. 
(2015). B-1a lymphocytes attenuate insulin resistance. Diabetes, 64(2), 593–603. 
http://doi.org/10.2337/db14-0554 
Soodini, G. R., & Hamdy, O. (2006). Pathophysiology of Diabetes in Obesity. In C. S. M. 
M. DSc (Ed.), Obesity and Diabetes (pp. 117–125). Humana Press. Retrieved 
from http://link.springer.com.ezproxy.bu.edu/chapter/10.1007/978-1-59259-985-
1_7 
Strissel, K. J., Stancheva, Z., Miyoshi, H., Perfield, J. W., DeFuria, J., Jick, Z., … Obin, 
M. S. (2007). Adipocyte Death, Adipose Tissue Remodeling, and Obesity 
Complications. Diabetes, 56(12), 2910–2918. http://doi.org/10.2337/db07-0767 
 39 
Vas, J., Grönwall, C., & Silverman, G. (2013). Fundamental roles of the innate-like 
repertoire of natural antibodies in immune homeostasis. B Cell Biology, 4, 4. 
http://doi.org/10.3389/fimmu.2013.00004 
Vo, H., Chiu, J., Allaimo, D., Mao, C., Wang, Y., Gong, Y., … Zhong, X. (2014a). High 
fat diet deviates PtC-specific B1 B cell phagocytosis in obese mice. Immunity, 
Inflammation and Disease, 2(4), 254–261. http://doi.org/10.1002/iid3.41 
Vo, H., Chiu, J., Allaimo, D., Mao, C., Wang, Y., Gong, Y., … Zhong, X. (2014b). High 
fat diet deviates PtC-specific B1 B cell phagocytosis in obese mice. Immunity, 
Inflammation and Disease, 2(4), 254–261. http://doi.org/10.1002/iid3.41 
Wilson, E. H., Katz, E., Goodridge, H. S., M. Harnett, M., & Harnett, W. (2003). In vivo 
activation of murine peritoneal B1 cells by the filarial nematode 
phosphorylcholine-containing glycoprotein ES-62. Parasite Immunology, 25(8-9), 
463–466. http://doi.org/10.1111/j.1365-3024.2003.00650.x 
Yamada, K., Ohki-Hamazaki, H., & Wada, K. (2000). Differential effects of social 
isolation upon body weight, food consumption, and responsiveness to novel and 
social environment in bombesin receptor subtype-3 (BRS-3) deficient mice. 
Physiology & Behavior, 68(4), 555–561. http://doi.org/10.1016/S0031-
9384(99)00214-0 
Yano, M., & Pirofski, L. (2011). Characterization of Gene Use and Efficacy of Mouse 
Monoclonal Antibodies to Streptococcus pneumoniae Serotype 8. Clinical and 
Vaccine Immunology, 18(1), 59–66. http://doi.org/10.1128/CVI.00368-10 
 40 
Yano, M., & Pirofski, L. -a. (2011). Characterization of Gene Use and Efficacy of Mouse 
Monoclonal Antibodies to Streptococcus pneumoniae Serotype 8. Clinical and 
Vaccine Immunology, 18(1), 59–66. http://doi.org/10.1128/CVI.00368-10 
Zhang, Y., Chung, Y., Bishop, C., Daugherty, B., Chute, H., Holst, P., … Dong, C. 
(2006). Regulation of T cell activation and tolerance by PDL2. Proceedings of the 
National Academy of Sciences, 103(31), 11695–11700. 
http://doi.org/10.1073/pnas.0601347103 
Zhong, X., & Rothstein, T. L. (2011). L2pB1: A new player in autoimmunity. Molecular 
Immunology, 48(11), 1292–1300. http://doi.org/10.1016/j.molimm.2010.12.006 
Zhong, X., Tumang, J. R., Gao, W., Bai, C., & Rothstein, T. L. (2007). PD-L2 expression 
extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 
and phosphatidylcholine binding. European Journal of Immunology, 37(9), 2405–
2410. http://doi.org/10.1002/eji.200737461 
 
 
 
 
 
 
 41 
CURRICULUM VITAE 
JORDAN ALISON NEWMARK 
Address: 1848 Commonwealth Ave, Apt. 23, Brighton, MA 02135 
Phone: (860) 463-7357 • Email: jordan.newmarjo@gmail.com 
Year of Birth: 1991 
EDUCATION           
Boston University, Graduate School of Medical Sciences       Boston, MA 
 Masters of Science in Medical Sciences Program; May 2016 (anticipated) 
 Current GPA 3.8 
University of Connecticut, College of Agriculture and Natural Resources   Storrs, CT 
Non-Degree Student, Animal Science; August – December 2013 
GPA 4.0, Dean’s List 
Boston College, College of Arts and Sciences         Chestnut Hill, MA 
Bachelor of Science in Psychology, Pre-Med Program; May 2013 
GPA 3.5, Honors Program 
 
PROFESSIONAL EXPERIENCE         
Zhong Lab at Boston Medical Center; Boston, MA 
Laboratory Manager           July 2015 – present  
• Manage ordering and inventory of all lab reagents and equipment 
• Schedule all core instruments needed for experiments 
• Organize mouse inventory and handle all breeding, transfer, and service requests 
• Make stock solutions and aliquots; autoclave materials; and maintain laboratory 
Stafford Springs Veterinary Clinic; Stafford Springs, CT    
Veterinary Technician          September 2013 – February 2014  
• Performed small surgeries; administered and monitored anesthesia; developed x-
rays; centrifuged blood for laboratory use; restrained animals; delivered vaccines 
and drew blood 
• Administered medications, food and water to animals; cleaned hospital 
• Handled clients; fulfilled clerical duties; completed lab forms and check-in sheets 
Neurobiology of Feeding Behavior Lab at Boston College; Chestnut Hill, MA 
Research Assistant/Thesis Student          January 2012 – May 2013 
• Sliced rat brains; stained, mounted, and coverslipped slides of tissue for analysis  
• Fed, weighed, and smeared laboratory rats; observed and performed perfusions 
• Counted orexin and fos-activated neurons to compile data for honors thesis 
Molecular Cell Biology Lab at Boston College; Chestnut Hill, MA 
Undergraduate Teacher’s Assistant                September 2011 – May 2012 
• Prepared lab materials for transformation and electrophoresis experiments; 
assisted graduate TAs  
• Directed students’ experiments and discussions; ran polymerase chain reaction 
(PCR) and collected results 
• Observed lab lectures, provided supervisor with feedback to improve lab course 
 
 42 
VOLUNTEER EXPERIENCE         
Veterinary Specialists of Connecticut; West Hartford, CT 
Volunteer                December 2012 – August 2013 
• Restrained animals; removed catheters, sutures and staples; ran blood screenings 
• Gained experience by observing surgeries, clinical interactions, ultrasounds, 
MRIs, dentals and endoscopies 
Second Chance Ranch; East Granby, CT 
Volunteer              June 2013 – August 2013 
• Fed, watered, and bathed horses; mucked out stalls, scrubbed water buckets, 
pitched hay 
• Learned how to properly harness, saddle, and lunge horses 
Angell Memorial Animal Hospital MSPCA; Boston, MA          
Dog Walker Volunteer         October 2012 – April 2013 
• Walked, fed and interacted with dogs; cleaned kennels, dishes and bedding 
Brigham and Women’s Hospital; Boston, MA        January 2012 – June 2012 
Volunteer, Central Transport 
• Delivered blood and other specimens from hospital rooms to laboratories 
Massachusetts General Hospital; Boston, MA 
Volunteer, Emergency Department Family Liaison        January 2010 – June 2012 
• Transported patients throughout hospital 
• Provided patient services, delivered meals, guided visitors to rooms 
Appalachia Volunteers/Habitat for Humanity; Harrisburg, PA  
Habitat for Humanity Volunteer             September 2010 – March 2011 
• Helped rebuild houses in Harrisburg, PA with students from Boston College 
St. Francis House; Boston, MA       
4Boston Volunteer        September 2009 – May 2010 
• Prepared and served lunch to the homeless in soup kitchen and homeless shelter 
 
ACTIVITIES            
Women in Science and Technology; Chestnut Hill, MA        
Co-Leader and Psychology Subject Leader         September 2011 – February 2013 
• Scheduled program lecturers, lunch and banquet preparation and handled finances  
• Directed the conduction of biology and psychology experiments; advised banquet 
presentation of the local high school girls’ experiences conducting experiments 
Eagle EMS; Chestnut Hill, MA       
EMT-B and Observer        September 2010 – May 2012 
• Applied medical aid as necessary at college events 
• Aided EMT’s in overnight ambulance rides with Armstrong Ambulance   
• Attended continuing education and general meetings 
Jemez Service Immersion Program; Chestnut Hill, MA      
Jemez-to-BC Host          September 2009 – November 2010 
• Hosted Jemez Pueblo high school girls to immerse them in the college experience 
by bringing them to classes, performing a variety of interactive activities and 
providing college information sessions 
 43 
PRESENTATIONS           
Boston Nutrition Obesity Research Center Symposium: Boston, MA      July 24, 2015 
Depletion of L2pB1 Cells Induces Accelerated Glucose Intolerance and Alteration of 
Natural IgM Immunoglobulin Repertoire 
• Authors: Jordan Newmark, Bruno Barros, Rebecca Lee, Hung Vo, Changchuin 
Mao, Wanwen Li, Xuemei Zhong 
• Hematology Oncology Section, Department of Medicine, Boston University 
Medical Center 
Honors Thesis: Chestnut Hill, MA       May 10, 2013 
Sex Differences in Orexin Activation Patterns of Fear-Cue Induced Inhibition of Eating 
in Rats 
• Author: Jordan Newmark 
• Behavioral Neuroscience Section, Department of Psychology, Boston College 
 
LABORATORY SKILLS          
• Antibody staining and mounting tissue; plasmid complementation and 
transformation; blotting; bacteria plating; gel electrophoresis; chromatography 
• Utilizing bioinformatics databases, microtome, centrifuge, spectrophotometer, 
microscope, embedding machine 
• Performing perfusions, laboratory animal husbandry duties and smearing  
• Running 9-color FACS panel and operating LSRII 
• Operating PC and Mac; Microsoft Word, Excel, Powerpoint; FlowJo 
 
 
 
 
 
 
 
 
 
 
 
 
